Lexeo announces common stock and warrants offering, no amount given

Lexeo Therapeutics (LXEO) announced that it has commenced an underwritten public offering and concurrent private placement of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Lexeo. Concurrent with the proposed public offering, Lexeo intends to sell shares of its common stock, and, in lieu of common stock, pre-funded warrants to purchase shares of its common stock, to Balyasny Asset Management in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, subject to consummation of the proposed public offering and other customary conditions. However, the consummation of the proposed public offering is not contingent on the consummation of the concurrent private placement. Leerink Partners, Cantor, Stifel and Oppenheimer & Co. are acting as joint book-running managers for the proposed public offering. Baird is acting as lead manager for the proposed public offering.